A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes

KURTOGLU E. L., KAYHAN B., GÜL M., KAYHAN B., Kayhan M. A., KARACA Z. M., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.8, pp.745-758, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 8
  • Publication Date: 2019
  • Doi Number: 10.5152/tjg.2019.18276
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.745-758
  • Keywords: Lipoxin A4, liver fibrosis, immune response, MKK4, MKK7, ATF2, A(4) RECEPTOR AGONIST, MOLECULAR-MECHANISMS, HEPATIC-FIBROSIS, INFLAMMATION, RESOLUTION, INSIGHTS, ANALOG, MKK4
  • Inonu University Affiliated: Yes

Abstract

Background/Aims: Lipoxin A4 (LXA4), an anti-inflammatory lipid mediator, regulates leukocyte cellular activity and activates gene transcription. The therapeutic effect of LXA4 on liver fibrosis and its mechanism on the immune system are largely unknown. Because the regenerative capacity of hepatocytes in acute and chronic liver failure models of mouse increases by silencing MKK4, we aimed to investigate the effect of parenteral administration of LXA4 on the genes responsible for regeneration of liver, namely MKK4, MKK7, and ATF2, and visualize the therapeutic effects in an experimental model.